Genentech Seeks Partners For Biomarker-Driven Drug Development Beyond Oncology
Executive Summary
Roche subsidiary hopes recent deals with 23andMe and Human Longevity for whole genome sequencing will help identify targets and biomarkers for Parkinson's disease and other non-cancer conditions. Firm also is taking a personalized medicine approach to development of treatments for pain, macular degeneration and asthma.